Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...

Som Chattopadhyay, national executive India, Amgen, said the first 300 employees were hired within 78 days of signing the contract for the new facility and another 300 are to be onboarded soon ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best drug stocks to buy now.

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other undervalued stocks. On March 5th, BBC reported that the US stock market had fallen after the ...

Global biotech leader Amgen opened its $200 million technology and innovation centre in Hyderabad, a facility that will help the U.S. firm ramp up digital capabilities, open more opportunities for ...